XPO evaluates candidates on three pillars: professional excellence (high intellect and passion), seriousness about work (mission-driven), and collegiality (kindness, humility, and a team-first attitude). This combination creates remarkable results.

When considering a new job, go beyond the role and culture. Analyze if you are strategically set up for success. This includes the company's competitive position, the budget and resources you'll have, and whether key leadership is backing you. A great role in a poor strategic setup will likely fail.

To build a resilient team during a tough economic period, CEO Sean Ainsworth prioritized finding people who deeply understood the 'why' behind the science and its patient impact. This created a committed core team that could navigate funding challenges when capital was scarce for unproven gene therapies.

Raj Devraj simplifies biotech venture evaluation into a four-part framework: scientific viability ("Will it work?"), market viability ("Will it sell?"), feasibility ("Can I do it in my lifetime?"), and execution capability ("Do I have the team?"). This provides a comprehensive yet concise due diligence checklist for early-stage opportunities.

When considering his first CEO role, Baldo strategically chose one that combined his passion for ophthalmology, a strong investor syndicate, promising clinical data, and a Phase 3 asset. This matched his self-identified "sweet spot" in late-stage drug development, creating an ideal entry point into a C-suite position.

Jade's CEO Tom Frohlich initially aimed to be a PhD biochemist but discovered he wasn't skilled at bench science. Instead of abandoning his passion, he pivoted to the pharmaceutical industry's business side. This allowed him to leverage his love for science while excelling in a commercial environment, demonstrating a successful model for recalibrating a scientific career.

For senior leaders, career moves should be curated around three pillars: the company culture and its authenticity ('People'), the product's innovation and market fit ('Product'), and the channel's potential for transformation and ecosystem expansion ('Partner').

Successful biotech teams are built on four pillars: genuine scientific curiosity, professional integrity to face data honestly (avoiding your own "Kool-Aid"), the ability to connect science to viable business outcomes, and a low-friction human environment free from politics and drama, which is the ultimate driver.

A successful biotech is built on a specific hierarchy of priorities. First, establish a clear and compelling vision. Second, bring in the right people with the right mindset. Third, ensure deep, intellectually honest science. Only then should you focus on building the operational infrastructure to support the first three pillars.